Elevance Health, Inc. $ELV Shares Acquired by Revisor Wealth Management LLC

Revisor Wealth Management LLC boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 162.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,010 shares of the company’s stock after purchasing an additional 2,482 shares during the quarter. Revisor Wealth Management LLC’s holdings in Elevance Health were worth $1,174,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in Elevance Health by 25.2% in the fourth quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock valued at $2,906,051,000 after purchasing an additional 1,668,679 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Elevance Health by 27.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after buying an additional 1,607,274 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Elevance Health by 10.0% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,032,751 shares of the company’s stock worth $1,764,231,000 after buying an additional 455,946 shares during the period. First Eagle Investment Management LLC grew its holdings in shares of Elevance Health by 0.6% during the fourth quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock worth $1,410,219,000 after buying an additional 24,271 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Elevance Health by 50.3% during the fourth quarter. Invesco Ltd. now owns 3,903,878 shares of the company’s stock worth $1,368,505,000 after buying an additional 1,306,390 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of ELV opened at $416.97 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The stock’s 50 day moving average is $391.29 and its two-hundred day moving average is $351.14. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $427.19. The firm has a market capitalization of $90.55 billion, a PE ratio of 17.74, a P/E/G ratio of 2.37 and a beta of 0.67.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the prior year, the business posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts anticipate that Elevance Health, Inc. will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were given a $1.72 dividend. The ex-dividend date was Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analysts Forecast Growth

Several analysts have commented on ELV shares. Mizuho upped their price objective on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Citigroup raised Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Barclays upped their price target on Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. Bank of America increased their price target on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a report on Thursday, June 4th. Finally, Sanford C. Bernstein boosted their price objective on shares of Elevance Health from $424.00 to $482.00 and gave the company an “outperform” rating in a research note on Thursday. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $419.16.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.34% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.